Single Doses GSK159797 On Patient Safety And Lung Function In Patients With Mild To Moderate Asthma

• Status: Completed
• Trial end date: 2004-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This study was designed to test safety aspects and effects on lung function of a new dry powder version of GSK159797 for asthmatic subjects to inhale. This will allow comparison with previous studies which have only used inhalation of the drug as a vapour.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: GlaxoSmithKline

Criteria

Inclusion criteria:

• Subjects with mild to moderate stable asthma but no other lung problems.

• Male subjects or females who are not able to get pregnant (e.g. post-menopausal or surgically sterile).

• Non-smokers.

• Subjects that show a measurable improvement in the function of their lungs after a single dose of salbutamol.

Exclusion criteria:

• Any significant illness.

• Subjects with heart problems.

• Subjects who have had a cold or chest infection 2-4 weeks prior to the study.

• Subjects who take medication for their asthma, or other conditions, not compatible with the study.